Loading...
•
Sep 30, 2024
Vaxart Q3 2024 Earnings Report
Announced business update and financial results for the third quarter of 2024.
Key Takeaways
Vaxart reported its Q3 2024 financial results, highlighting the ongoing progress with the COVID-19 vaccine program, including the near completion of enrollment for the sentinel cohort in the Phase 2b study. The company also received feedback from the FDA on its norovirus program and is evaluating next steps.
Sentinel cohort dosing was successfully initiated, keeping the company on track with BARDA contract milestones.
Enrollment of the sentinel cohort is expected to be completed in November 2024.
Constructive feedback was received from the FDA on the norovirus program, and next steps are being evaluated.
Potentially more potent norovirus GI.1 and GII.4 constructs were created by the scientific team.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...